REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksInspiration Hlt Regulatory News (IHC)

Share Price Information for Inspiration Hlt (IHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 16.00
Bid: 15.50
Ask: 16.50
Change: -0.75 (-4.48%)
Spread: 1.00 (6.452%)
Open: 16.75
High: 16.75
Low: 15.75
Prev. Close: 16.75
IHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Strategic acquisition of Airon Corporation

4 Jan 2024 07:00

RNS Number : 5890Y
Inspiration Healthcare Group PLC
04 January 2024
 

 

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014 as amended by the Market Abuse (Amendment) (EU Exit) Regulations 2019. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

 

 

Inspiration Healthcare Group plc

("Inspiration Healthcare" or the "Company" or the "Group")

 

Launch of Inspiration Healthcare's USA platform through

strategic acquisition of Airon Corporation

Highlights

· Provides an established platform to accelerate Inspiration Healthcare's commercial strategy in the USA and the rest of North America

· Adds a complementary portfolio of FDA cleared products

· Acquisition expected to be earnings accretive in the second full year of ownership

 

Inspiration Healthcare (AIM: IHC), the global medical technology company, announces the acquisition of Airon Corporation ("Airon") a specialist respiratory device company based in Florida, USA for a maximum consideration of $2.5m. The consideration includes an initial upfront cash payment of $1.5m plus an earn out of up to $1.0m dependent on the delivery of future revenues.

 

Overview of Airon

Airon is a leading manufacturer of specialist pneumatic oxygen-powered life support ventilators, which have multiple uses including in Magnetic Resonance Imaging (MRI) machines and transportation for neonates through to adults. The company also sells a complementary range of continuous positive airway pressure ("CPAP") devices, used in emergency medicine to support children and adult patients. Airon has 15 employees, including sales, marketing and tech support, and an established distribution network across the USA. In the year to 30 April 2023, Airon generated total revenues of $1.4m, a loss before tax of $0.4m and net assets of $1.3m.

 

Strategic rationale for the acquisition

The acquisition is in line with Inspiration Healthcare's long-term strategy to acquire companies with both complementary technologies and sales reach to expand the Group's global footprint, add scale and accelerate growth. The USA is a significant strategic market for the Group and the acquisition provides an established platform to support and de-risk the Company's commercial strategy. It is expected to be earnings accretive in the second full year of ownership.

 

In August 2023, Inspiration Healthcare submitted a 510K application to the FDA for the SLE6000 neonatal ventilator which, pending approval, it aims to launch in H2 FY2025. The acquisition of Airon provides an established platform for US market entry for the SLE6000 and other products in the Company's portfolio, enabling the Group to leverage Airon's established US presence, brand, and reputation for high quality specialist products. The Group will also add the Airon products to its portfolio to drive sales across its wider global distribution network.

 

The benefits of the enlarged group include:

 

· An established operation, in Melbourne, Florida with warehousing facilities, proven systems and processes for the US market and access to key neonatal units across the USA

· A recognised brand and experienced sales team and distributor network targeting the same customers

· A portfolio of complementary FDA cleared products that will allow further growth in the USA

· Synergistic neonatal products that can be sold through the Group's existing international sales channels

· Support for the Group's commercial strategy in Canada

· Expected to be earnings accretive from the second full financial year of ownership

 

Terms of acquisition

Inspiration has acquired Airon for $1.5m cash paid at completion. An earn out of up to $1.0m cash is payable based on Airon achieving certain net sales targets in the 12 months to 30 April 2025.

 

The acquisition will be funded through the Company's existing resources.

 

Eric Gjerde, founder, President, and CEO of Airon will stay involved in the company to help manage the transition whilst Inspiration Healthcare search for a permanent new General Manager for the North American business as the Group looks to invest in the business in the forthcoming years.

 

Neil Campbell, CEO of Inspiration Healthcare, commented: "The acquisition of Airon is an important strategic milestone for Inspiration Healthcare. The potential approval of the SLE6000 represents a significant commercial opportunity and Airon gives the Group an established direct presence and expertise in the USA, which will accelerate and de-risk our commercial strategy. Airon also brings a range of complementary products, which will further enhance our portfolio and enable us to increase sales in other markets. I am delighted to welcome the Airon team to Inspiration Healthcare and look forward to working together to provide lifesaving technologies to the US market." 

 

Eric Gjerde, founder, President, and CEO of Airon said: "I am excited that Airon is joining Inspiration Healthcare. The Group has a strong portfolio of best-in-class products that will be of significant value to our customers. I would like to thank our customers and staff for their continued support as Airon embarks on the next part of its journey."

 

For further information:

 

Inspiration Healthcare Group plc

Tel: +44 (0)330 175 0000

Neil Campbell, Chief Executive Officer

Alan Olby, Chief Financial Officer

Liberum (Nominated Adviser & Broker)

Tel: +44 (0)20 3100 2000

Phil Walker

Richard Lindley

Will King

 

Walbrook PR Ltd (Media and Investor Relations)

Tel: +44 (0)20 7933 8780 or inspirationhealthcare@walbrookpr.com

Anna Dunphy

Mob: +44 (0) 7876 741 001

Stephanie Cuthbert

Mob: +44 (0) 7796 794 663

Louis Ashe-Jepson

Mob: +44 (0) 7747 515 393

 

 

About Inspiration Healthcare

Inspiration Healthcare (AIM: IHC) designs, manufactures and markets pioneering medical technology. Based in the UK, the Company specialises in neonatal intensive care medical devices, which are addressing a critical need to help to save the lives and improve the outcomes of patients, starting with the very first breaths of life.

 

The Company has a broad portfolio of its own products and complementary distributed products, for use in neonatal intensive care designed to support even the most premature babies throughout their hospital stay. Its own branded products range from highly sophisticated capital equipment such as ventilators for life support through to single-use disposables.

 

The Company sells its products directly to hospitals and healthcare providers in the UK and Ireland, where it also distributes a range of advanced medical technologies for infusion therapy. In the rest of the world the Company has an established network of distribution partners around the world giving access to more than 75 countries.

 

The Company operates from its world-class Manufacturing and Technology Centre in Croydon, South London and from its facility in Hailsham, East Sussex.

 

Further information on Inspiration Healthcare can be found at www.inspirationhealthcaregroup.com

 

About Airon

Established in 1997, Airon Corporation proudly manufactures products in Melbourne, Florida and markets their innovative, reliable, effective, high technology pneumatic oxygen-powered life support ventilation and CPAP products and accessories throughout the world. Their products support neonates, infants, paediatrics, children and adult patients in EMS, hospital ER and trauma, MRI, OR, ICU and transport.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQUOAURSBUARUR
Date   Source Headline
28th Nov 20229:00 amRNSPrice Monitoring Extension
28th Nov 20227:00 amRNSUpdate on Trading
9th Nov 20227:00 amRNSUkraine Order
4th Oct 20224:40 pmRNSSecond Price Monitoring Extn
4th Oct 20224:35 pmRNSPrice Monitoring Extension
4th Oct 20222:05 pmRNSSecond Price Monitoring Extn
4th Oct 20222:00 pmRNSPrice Monitoring Extension
4th Oct 202211:05 amRNSSecond Price Monitoring Extn
4th Oct 202211:00 amRNSPrice Monitoring Extension
4th Oct 20227:00 amRNSInterim Results
21st Sep 20227:00 amRNSSignificant Japanese Order
1st Sep 20227:00 amRNSResults date and Investor events
15th Aug 20227:00 amRNSTrading Update
13th Jul 20227:00 amRNSCapital Markets Day
30th Jun 202212:58 pmRNSResult of AGM
30th Jun 20227:00 amRNSAGM Statement
10th Jun 20221:00 pmRNSExercise of options and Total Voting Rights
7th Jun 20227:00 amRNS£1.3 million Iraq Order
6th Jun 20227:00 amRNSAnnual Report 2022 and Notice of AGM
24th May 20227:00 amRNSTR1 Notification
20th May 20223:09 pmRNSTR1 Notification
19th May 20227:00 amRNSMello Investor Conference
4th May 20227:00 amRNSFinal Results
25th Apr 20227:05 amRNSInvestor Presentation
8th Apr 20222:21 pmRNSGrant of Options
1st Apr 20227:00 amRNSLaunch of test to avoid hearing loss in neonates
17th Feb 20227:00 amRNSPost Period Trading Update and Notice of Results
14th Feb 20227:00 amRNS$1.37 million Egyptian Order
1st Feb 20229:00 amRNSCenkos Virtual Growth and Innovation Forum
9th Dec 20214:15 pmRNSTR1 Notification
9th Dec 20214:15 pmRNSTR1 Notification
2nd Dec 20217:00 amRNSCapital Markets Day
29th Oct 20213:07 pmRNSDirector/PDMR Shareholding
25th Oct 202110:15 amRNSReplacement: Director/PDMR Shareholding
22nd Oct 20214:35 pmRNSDirector/PDMR Shareholding
20th Oct 20215:02 pmRNSDirector/PDMR Shareholding
5th Oct 20217:00 amRNSInterim Results
4th Oct 20217:00 amRNSTR1 Notification
24th Sep 20217:00 amRNSNotice of Results, Mello and AIM Awards
11th Aug 20217:00 amRNSTrading Update
27th Jul 202110:13 amRNSDirector/PDMR Shareholding
12th Jul 20217:00 amRNSTR1 Notification
25th Jun 202112:43 pmRNSResult of AGM
25th Jun 20217:00 amRNSAGM Statement
23rd Jun 20211:15 pmRNSAGM Notice
22nd Jun 20217:00 amRNSProject WAVE recruits first patient
16th Jun 20219:18 amRNSDirector/PDMR Shareholding
16th Jun 20217:00 amRNSCapital Markets Day
28th May 20217:00 amRNSAnnual Report 2021 and Notice of AGM
20th May 20212:15 pmRNSMello Healthcare Presentation 25th May 2021

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.